Author

A. Wiita

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Barpanda· 1 shared A. Diaz· 1 shared A. Du· 1 shared A. Kang· 1 shared A. Kishishita· 1 shared A. Saijo· 1 shared A. Yamamichi· 1 shared B. Hann· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Barpanda

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 19, 2023

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

D. W. Kwok, N. O. Stevers, T. Nejo…·H. Okada

The paper identifies tumor-wide splicing aberrations that generate public neoantigens, enabling T-cell-based immunotherapies targeting intratumoral heterogeneity.

DOI 10.1101/2023.10.19.563178

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 4, 2021

Functional multi-omics reveals genetic and pharmacologic regulation of surface CD38 in multiple myeloma

P. Choudhry, C. Kasap, B. Patino Escobar…·A. Wiita

This study uses multi-omics approaches to identify regulators of CD38 surface expression in multiple myeloma and assess the impact of therapies on CD38 levels and signaling.

DOI 10.1101/2021.08.04.455165

humanscRNA-seq

𝕏 PostBluesky